Department of Hepatopancreatobiliary and Transplant Surgery, Singapore General Hospital, 20 College Road, Singapore.
Hepatobiliary and Liver Transplant Unit, Hospital Universitario Cruces, Cruces Plaza, S/N, 48903, Barakaldo, Bizkaia, Spain; BioCruces Research Institute, University of the Basque Country, Cruces Plaza, 48903, Barakaldo, Bizkaia, Spain.
HPB (Oxford). 2021 Aug;23(8):1164-1174. doi: 10.1016/j.hpb.2021.01.009. Epub 2021 Jan 29.
This systematic review and meta-analysis aimed to compare the outcomes of curative therapy (resection, transplantation, ablation) for hepatocellular carcinoma (HCC) arising from non-alcoholic fatty liver disease (NAFLD) and non-NAFLD etiologies.
A systematic search of PubMed, EMBASE and Cochrane Library was conducted for studies comparing survival, peri- and post-operative outcomes. Quality assessment was performed using the Newcastle-Ottawa scale.
Findings for 5579 patients were pooled across 9 studies and examined. Analysis demonstrated improved disease-free survival (DFS; HR 0.85, 95% CI 0.74-0.98, p = 0.03) and overall survival (OS; HR 0.87; 95% CI 0.81-0.93; p < 0.0001) in NAFLD-HCC patients undergoing liver resection as compared to non-NAFLD HCC patients. NAFLD-HCC patients undergoing all forms of curative therapy were similarly associated with improved OS (HR 0.96; 95% CI 0.86-1.06; p = 0.40) and DFS (HR 0.85; 95% CI 0.74-0.98; p = 0.03), albeit results being significant only for DFS. Only 2 studies reported higher rates of peri- and post-operative complications in patients with NAFLD-HCC. Significant inter-study heterogeneity precluded further analysis.
NAFLD-HCC patients can enjoy long-term survival benefit with aggressive curative therapy. Peri- and post-operative morbidity should be mitigated with pre-operative optimization of comorbidities, and deliberately close post-operative monitoring.
本系统评价和荟萃分析旨在比较非酒精性脂肪性肝病(NAFLD)和非 NAFLD 病因引起的肝细胞癌(HCC)的治愈性治疗(切除、移植、消融)的结果。
对 PubMed、EMBASE 和 Cochrane Library 进行了系统检索,以比较生存、围手术期和术后结局的研究。使用纽卡斯尔-渥太华量表进行质量评估。
对 9 项研究中 5579 例患者的研究结果进行了汇总和分析。分析显示,NAFLD-HCC 患者行肝切除术后无疾病生存率(DFS;HR 0.85,95%CI 0.74-0.98,p=0.03)和总生存率(OS;HR 0.87;95%CI 0.81-0.93;p<0.0001)均有改善。NAFLD-HCC 患者接受所有形式的治愈性治疗与 OS(HR 0.96;95%CI 0.86-1.06;p=0.40)和 DFS(HR 0.85;95%CI 0.74-0.98;p=0.03)的改善相关,但DFS 结果仅具有统计学意义。只有 2 项研究报告 NAFLD-HCC 患者的围手术期和术后并发症发生率较高。由于研究间存在显著异质性,因此无法进一步分析。
NAFLD-HCC 患者可通过积极的治愈性治疗获得长期生存获益。应通过术前优化合并症和术后密切监测来减轻围手术期和术后发病率。